Literature DB >> 27278064

Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria.

Takafumi Hosokawa1, Hideto Nakajima2, Kiichi Unoda2, Kazushi Yamane2, Yoshimitsu Doi2, Shimon Ishida2, Fumiharu Kimura2, Toshiaki Hanafusa2.   

Abstract

Guillain-Barré syndrome (GBS) is categorized into two major subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). However, a proportion of patients are electrophysiologically unclassified because of electrophysiological findings that do not fulfil AIDP or AMAN criteria, and underlying pathophysiological mechanisms and lesion distributions of unclassified patients are not well defined. The aims of this study are to elucidate disease pathophysiology and lesion distribution in unclassified patients. We retrospectively studied 48 consecutive GBS patients. Patients were classified on the basis of initial electrophysiological findings according to Ho's criteria. Clinical and serial electrophysiological examinations of unclassified patients were conducted. Twelve (25 %) GBS patients were unclassified. All unclassified patients were able to walk independently at 21 days after onset. No unclassified patients, except one patient with diabetes mellitus, had sensory nerve involvement. Eight patients underwent a follow-up study within 15 days of the initial study. Distal motor latencies (DMLs) of the left median motor nerve were found to be significantly and uniformly decreased compared with initial studies (p = 0.008). DMLs (p < 0.0001) and distal compound action potential (CMAP) durations (p = 0.002) of all nerves were significantly decreased, and distal CMAP amplitudes (p = 0.026) significantly increased compared with initial studies. In unclassified GBS patients, DML values during initial electrophysiological studies would be prolonged compared with expected values in the same patient unaffected by GBS and later improve rapidly with increased distal CMAP amplitudes without the development of excessive temporal dispersions. Lesions are also present in distal nerve segments caused by reversible conduction failure.

Entities:  

Keywords:  AIDP; AMAN; Guillain-Barré syndrome; Reversible conduction failure

Mesh:

Year:  2016        PMID: 27278064     DOI: 10.1007/s00415-016-8192-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

Review 1.  Guillain-Barré syndrome.

Authors:  Nobuhiro Yuki; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

Review 2.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group.

Authors: 
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

4.  Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies.

Authors:  S Kuwabara; K Ogawara; K Mizobuchi; M Koga; M Mori; T Hattori; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

5.  Early electrodiagnostic findings in Guillain-Barré syndrome.

Authors:  P H Gordon; A J Wilbourn
Journal:  Arch Neurol       Date:  2001-06

6.  Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction.

Authors:  M Baba; M Matsunaga
Journal:  Electromyogr Clin Neurophysiol       Date:  1984 Nov-Dec

7.  Conduction block in acute motor axonal neuropathy.

Authors:  Norito Kokubun; Momoka Nishibayashi; Antonino Uncini; Masaaki Odaka; Koichi Hirata; Nobuhiro Yuki
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

Review 8.  Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.

Authors:  N Yuki
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

9.  An acute axonal form of Guillain-Barré polyneuropathy.

Authors:  T E Feasby; J J Gilbert; W F Brown; C F Bolton; A F Hahn; W F Koopman; D W Zochodne
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  5 in total

Review 1.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

2.  Re-evaluating the accuracy of optimized electrodiagnostic criteria in very early Guillain-Barré syndrome: a sequential study.

Authors:  Velina Nedkova; Gerardo Gutiérrez-Gutiérrez; Francisco J Navacerrada-Barrero; José Berciano; Carlos Casasnovas
Journal:  Acta Neurol Belg       Date:  2021-02-18       Impact factor: 2.396

3.  Integrated Chinese and Western Medicine for Acute Guillain-barré Syndrome Treatment.

Authors:  Liu Yang; Xiumin Zhao
Journal:  Transl Neurosci       Date:  2020-02-29       Impact factor: 1.757

Review 4.  Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects.

Authors:  Nowshin Papri; Zhahirul Islam; Sonja E Leonhard; Quazi D Mohammad; Hubert P Endtz; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2021-03-01       Impact factor: 42.937

5.  Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Taiki Sawai; Yoshitsugu Nakamura; Eri Sano; Akihiro Tsukahara; Kiichi Unoda; Shimon Ishida; Sadaki Sakane; Fumiharu Kimura; Shigeki Arawaka
Journal:  BMC Neurol       Date:  2020-05-27       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.